Enfuvirtide T-20

Modify Date: 2024-01-02 16:45:28

Enfuvirtide T-20 structure	Common Name	Enfuvirtide T-20
	CAS Number	159519-65-0	Molecular Weight	4491.88000
	Density	1.59g/cm3	Boiling Point	N/A
	Molecular Formula	C₂₀₄H₃₀₁N₅₁O₆₄	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Enfuvirtide T-20

Enfuvirtide is an anti-HIV-1 fusion inhibitor peptide. Sequence: Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2.

Name	enfuvirtide
Synonym	More Synonyms

Description	Enfuvirtide is an anti-HIV-1 fusion inhibitor peptide. Sequence: Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2.
Related Catalog	Signaling Pathways >> Anti-infection >> HIV Peptides Research Areas >> Infection
Target	HIV fusion[1]
In Vitro	A cell-cell fusion assay reveals that the effective concentration for achieving 50% inhibition (IC50) of Enfuvirtide is 23 ± 6 nM[2]. IFN-λs (1, 2, or 3) or the antiretrovirals (AZT, Efavirenz, Indinavir, and Enfuvirtide) significantly inhibita the expression of HIV p24 antigen and Gag gene in macrophages. IFN-λs (1, 2, or 3) also enhanced the anti-HIV (Bal) effect of AZT, Efavirenz, Indinavir, and Enfuvirtide[3].
In Vivo	Enfuvirtide has a T1/2 of 3.8 h[2].
Animal Admin	For infection with the resistant HIV strains, 7-day-cultured macrophages (105 cells/well in 96-well plates) are incubated with or without IFN-λ1, λ2, or λ3 (100 ng/mL each) and/or anti-HIV drugs: Azidothymidine (AZT) 10 pM; Efavirenz 100 pM; Indinavir 10-3 pM, and Enfuvirtide 10 nM for 24 h. Cells are then infected with different strains of HIV (6 ng p24/well) for 2 h. After washed three times with plain DMEM, cells are cultured with fresh 10% DMEM containing IFN-λs and/or antiretroviral drugs. For HIV Bal infection, culture supernatant is harvested at day 8 post infection for RT and p24 assays. Infected and untreated cells served as controls. HIV Gag gene expression in infected cells is also examined at day 8 post infection. For anti-HIV drug-resistant virus (A012 G691-6 or TC49) infection, culture supernatant is harvested for HIV p24 protein by ELISA at days 3, 5, 7, and 10 postinfection. The cell cultures are replaced with the fresh media supplemented with IFN-λ1, λ2, or λ3 and/or the antiretrovirals every 2–3 days. The culture supernatant collected at day 10 postinfection is also subjected to RT assay[3].
References	[1]. Figueira TN, et al. Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance. Sci Rep. 2017 Mar 30;7:45647. [2]. Cao P, et al. The improved efficacy of Sifuvirtide compared with Enfuvirtide might be related to its selectivity for the rigid biomembrane, as determined through surface plasmon resonance. PLoS One. 2017 Feb 16;12(2):e0171567. [3]. Wang X, et al. IFN-λ Inhibits Drug-Resistant HIV Infection of Macrophages. Front Immunol. 2017 Mar 6;8:210.

Density	1.59g/cm3
Molecular Formula	C₂₀₄H₃₀₁N₅₁O₆₄
Molecular Weight	4491.88000
Exact Mass	4489.19000
PSA	1902.89000
LogP	5.69700
Storage condition	?20°C

T-20

Enfuvirtide Acetate (T-20)

enfuvirtide

UNII-19OWO1T3ZE

Fuzeon

DP178

acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-isoleucyl-L-histidyl-L-seryl-L-leucyl-L-isoleucyl-L-a-glutamyl-L-a-glutamyl-L-seryl-L-glutaminyl-L-asparaginyl-L-glutaminyl-L-glutaminyl-L-a-glutamyl-L-lysyl-L-asparaginyl-L-a-glutamyl-L-glutaminyl-L-a-glutamyl-L-leucyl-L-leucyl-L-a-glutamyl-L-leucyl-L-a-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-asparaginyl-L-tryptophyl-L-phenylalaninamide

Pentafuside

T 20 (peptide)

Enfuvirtide Acetate